Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Tuesday, January 13, 2026, 10:30 AM–11:10 AM PT at The Westin St. Francis, Georgian Room. A live webcast and archived replay will be available on the company website at https://ir.vorbio.com/events-presentations/. The company is clinical-stage and focuses on autoimmune disease treatments.
Positive
- None.
Negative
- None.
News Market Reaction – VOR
In the Jan 6 session, VOR gained 10.30%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.3% during that session. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Board appointments | Neutral | -1.3% | New investor-affiliated directors join board following prior PIPE financing. |
| Dec 15 | Private placement | Neutral | +8.0% | Announced $150M private placement to fund telitacicept Phase 3 programs. |
| Nov 13 | Earnings & update | Neutral | -3.1% | Q3 2025 results with positive telitacicept data and large non-cash warrant loss. |
| Nov 10 | Offering priced | Neutral | +0.5% | Pricing of $100M underwritten stock offering at $10.00 per share. |
| Nov 10 | Offering announced | Neutral | +0.5% | Proposed $100M equity offering using effective shelf registration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financings and corporate updates often saw modest price moves, with no consistent pattern of strong rallies or selloffs on news.
Over the last few months, Vor Bio has focused on financing and governance moves supporting its telitacicept‑centered autoimmune strategy. In November 2025, it announced and priced a $100M public offering under its shelf. Subsequent Q3 2025 results highlighted large non‑cash warrant impacts and funding into Q2 2027. A $150M private placement in December 2025 further strengthened resources, followed by new board appointments tied to key investors. Today’s conference participation fits into this ongoing investor‑relations and visibility push.
Key Terms
autoimmune diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT
Location: The Westin St. Francis, Georgian Room
A live webcast and archived replay of the presentation will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
